The price of Acadia Pharmaceuticals Inc (NASDAQ: ACAD) closed at $23.81 in the last session, up 0.25% from day before closing price of $23.75. In other words, the price has increased by $+0.06 from its previous closing price. On the day, 1294652 shares were traded.
Ratios:
We take a closer look at ACAD’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.94 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 235.63. For the most recent quarter (mrq), Quick Ratio is recorded 2.28 and its Current Ratio is at 2.42. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on January 30, 2024, initiated with a Outperform rating and assigned the stock a target price of $40.
On January 24, 2024, Needham Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $37.
Morgan Stanley Upgraded its Equal-Weight to Overweight on December 19, 2023, whereas the target price for the stock was revised from $31 to $40.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 26 when DAVIS STEPHEN sold 5,577 shares for $24.67 per share. The transaction valued at 137,585 led to the insider holds 101,890 shares of the business.
Schneyer Mark C. sold 772 shares of ACAD for $19,045 on Feb 26. The EVP, CHIEF FINANCIAL OFFICER now owns 21,067 shares after completing the transaction at $24.67 per share. On Feb 26, another insider, Teehan Brendan, who serves as the EVP, COO, HEAD OF COMMERCIAL of the company, sold 624 shares for $24.67 each. As a result, the insider received 15,394 and left with 31,432 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACAD now has a Market Capitalization of 3.92B and an Enterprise Value of 3.54B. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.40 while its Price-to-Book (P/B) ratio in mrq is 9.08. Its current Enterprise Value per Revenue stands at 4.87 whereas that against EBITDA is -52.19.
Stock Price History:
Over the past 52 weeks, ACAD has reached a high of $33.99, while it has fallen to a 52-week low of $17.71. The 50-Day Moving Average of the stock is 27.34, while the 200-Day Moving Average is calculated to be 25.60.
Shares Statistics:
According to the various share statistics, ACAD traded on average about 1.96M shares per day over the past 3-months and 1.96M shares per day over the past 10 days. A total of 164.65M shares are outstanding, with a floating share count of 163.51M. Insiders hold about 0.76% of the company’s shares, while institutions hold 97.15% stake in the company. Shares short for ACAD as of Feb 15, 2024 were 9.42M with a Short Ratio of 4.80, compared to 8.11M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.72% and a Short% of Float of 7.64%.
Earnings Estimates
The company has 19 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.07 for the current quarter, with a high estimate of $0.26 and a low estimate of -$0.08, while EPS last year was -$0.27. The consensus estimate for the next quarter is $0.21, with high estimates of $0.39 and low estimates of $0.11.
Analysts are recommending an EPS of between $1.17 and $0.3 for the fiscal current year, implying an average EPS of $0.68. EPS for the following year is $1.4, with 20 analysts recommending between $2.49 and $0.79.
Revenue Estimates
According to 19 analysts, the current quarter’s revenue is expected to be $209.93M. It ranges from a high estimate of $235.9M to a low estimate of $201.3M. As of the current estimate, Acadia Pharmaceuticals Inc’s year-ago sales were $118.46M, an estimated increase of 77.20% from the year-ago figure. For the next quarter, 19 analysts are estimating revenue of $242.1M, an increase of 53.40% less than the figure of $77.20% in the same quarter last year. There is a high estimate of $253M for the next quarter, whereas the lowest estimate is $235.9M.
A total of 21 analysts have provided revenue estimates for ACAD’s current fiscal year. The highest revenue estimate was $989.5M, while the lowest revenue estimate was $939M, resulting in an average revenue estimate of $967.36M. In the same quarter a year ago, actual revenue was $726.44M, up 33.20% from the average estimate. Based on 20 analysts’ estimates, the company’s revenue will be $1.13B in the next fiscal year. The high estimate is $1.31B and the low estimate is $993.2M. The average revenue growth estimate for next year is up 17.30% from the average revenue estimate for this year.
